Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy.
Im NG, Guillaumet-Adkins A, Wal M, Rogers AJ, Frede J, Havig CC, Yang J, Anand P, Stegmann SK, Waldschmidt JM, Sotudeh N, Niu L, Voisine J, Schweiger MR, Grassberger C, Lohr JG, Knoechel B. Im NG, et al. Among authors: waldschmidt jm. Cancer Immunol Res. 2022 Sep 1;10(9):1055-1068. doi: 10.1158/2326-6066.CIR-21-0626. Cancer Immunol Res. 2022. PMID: 35759797 Free PMC article.
Tracking myeloma tumor DNA in peripheral blood.
Waldschmidt JM, Vijaykumar T, Knoechel B, Lohr JG. Waldschmidt JM, et al. Best Pract Res Clin Haematol. 2020 Mar;33(1):101146. doi: 10.1016/j.beha.2020.101146. Epub 2020 Jan 14. Best Pract Res Clin Haematol. 2020. PMID: 32139012 Free PMC article. Review.
Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma.
Waldschmidt JM, Kloeber JA, Anand P, Frede J, Kokkalis A, Dimitrova V, Potdar S, Nair MS, Vijaykumar T, Im NG, Guillaumet-Adkins A, Chopra N, Stuart H, Budano L, Sotudeh N, Guo G, Grassberger C, Yee AJ, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG. Waldschmidt JM, et al. Clin Cancer Res. 2021 Dec 1;27(23):6432-6444. doi: 10.1158/1078-0432.CCR-21-2040. Epub 2021 Sep 13. Clin Cancer Res. 2021. PMID: 34518309 Free PMC article.
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma.
Frede J, Anand P, Sotudeh N, Pinto RA, Nair MS, Stuart H, Yee AJ, Vijaykumar T, Waldschmidt JM, Potdar S, Kloeber JA, Kokkalis A, Dimitrova V, Mann M, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG. Frede J, et al. Among authors: waldschmidt jm. Nat Cell Biol. 2021 Nov;23(11):1199-1211. doi: 10.1038/s41556-021-00766-y. Epub 2021 Oct 21. Nat Cell Biol. 2021. PMID: 34675390 Free PMC article.
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.
Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, Bianchi G, Guo G, Potdar S, Seifer C, Nair MS, Kokkalis A, Kloeber JA, Shapiro S, Budano L, Mann M, Friedman R, Lipe B, Campagnaro E, O'Donnell EK, Zhang CZ, Laubach JP, Munshi NC, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG. Waldschmidt JM, et al. Leukemia. 2022 Apr;36(4):1078-1087. doi: 10.1038/s41375-021-01492-y. Epub 2022 Jan 13. Leukemia. 2022. PMID: 35027656 Free PMC article. Clinical Trial.
Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.
Eismann J, Heng YJ, Waldschmidt JM, Vlachos IS, Gray KP, Matulonis UA, Konstantinopoulos PA, Murphy CJ, Nabavi S, Wulf GM. Eismann J, et al. Among authors: waldschmidt jm. J Cancer Res Clin Oncol. 2020 Feb;146(2):503-514. doi: 10.1007/s00432-019-03078-9. Epub 2019 Nov 19. J Cancer Res Clin Oncol. 2020. PMID: 31745703 Free PMC article.
Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma.
Waldschmidt JM, Fruttiger SJ, Wider D, Jung J, Thomsen AR, Hartmann TN, Duyster J, Hug MJ, Azab KA, Jung M, Wäsch R, Engelhardt M. Waldschmidt JM, et al. J Cancer Res Clin Oncol. 2022 May;148(5):1045-1055. doi: 10.1007/s00432-021-03854-6. Epub 2022 Jan 24. J Cancer Res Clin Oncol. 2022. PMID: 35072775 Free PMC article.
Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).
Waldschmidt JM, Keller A, Ihorst G, Grishina O, Müller S, Wider D, Frey AV, King K, Simon R, May A, Tassone P, Duyster J, Jung M, Raje N, Wäsch R, Engelhardt M. Waldschmidt JM, et al. Haematologica. 2018 Oct;103(10):e473-e479. doi: 10.3324/haematol.2018.189969. Epub 2018 Apr 19. Haematologica. 2018. PMID: 29674494 Free PMC article. Clinical Trial. No abstract available.
30 results